OPA1: How much do we know to approach therapy? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pharmacol Res Année : 2018

OPA1: How much do we know to approach therapy?

Valentina del Dotto
  • Fonction : Auteur
Mario Fogazza
  • Fonction : Auteur
Michela Rugolo
  • Fonction : Auteur
Valerio Carelli
Claudia Zanna
  • Fonction : Auteur

Résumé

OPA1 is a GTPase that controls several functions, such as mitochondrial dynamics and energetics, mtDNA maintenance and cristae integrity. In the last years, there have been described other cellular pathways and mechanisms involving OPA1 directly or through its interaction. All this new information, by implementing our knowledge on OPA1 is instrumental to elucidating the pathogenic mechanisms of OPA1 mutations. Indeed, these are associated with dominant optic atrophy (DOA), one of the most common inherited optic neuropathies, and with an increasing number of heterogeneous neurodegenerative disorders. In this review, we overview all recent findings on OPA1 protein functions, on its dysfunction and related clinical phenotypes, focusing on the current therapeutic options and future perspectives to treat DOA and the other associated neurological disorders due to OPA1 mutations.

Domaines

Organes des sens
Fichier non déposé

Dates et versions

hal-01964574 , version 1 (22-12-2018)

Identifiants

Citer

Valentina del Dotto, Mario Fogazza, Guy Lenaers, Michela Rugolo, Valerio Carelli, et al.. OPA1: How much do we know to approach therapy?. Pharmacol Res, 2018, 131, pp.199-210. ⟨10.1016/j.phrs.2018.02.018⟩. ⟨hal-01964574⟩
43 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More